PERIKABIVEN is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].
The recommended dosage of PERIKABIVEN in adults is 27 to 40 mL/kg/day. The amount of macronutrients provided by PERIKABIVEN are shown in Table 1.
The maximum daily dosage of PERIKABIVEN in adults should not exceed 40 mL/kg/day.
In patients with serum triglyceride concentrations above 400 mg/dL, stop the PERIKABIVEN infusion and monitor serum triglyceride levels. Once the triglycerides are <400 mg/dL, restart PERIKABIVEN at a lower infusion rate and advance rate in smaller increments towards target dosage, checking the triglyceride levels prior to each adjustment [see Contraindications (4) and Warnings and Precautions (5.13)].
Treatment with PERIKABIVEN may be continued for as long as is required by the patient's condition.
In patients with renal impairment, the dosage of PERIKABIVEN should be the recommended adult dosage (see above). Prior to administration, correct severe fluid or electrolyte imbalances. Closely monitor serum electrolyte levels and adjust the volume of PERIKABIVEN administered as required [see Warnings and Precautions (5.12)].
Renal patients not needing dialysis require 0.6 to 0.8 g of protein/kg/day. Patients on dialysis or continuous renal replacement therapy should receive 1.2 to 1.8 g of protein/kg/day up to a maximum of 2.5 g of protein/kg/day based on nutritional status and estimated protein losses. The PERIKABIVEN dosage can be adjusted based on the treatment for the renal impairment, supplementing protein as indicated. Additional protein may be added to PERIKABIVEN bag or infused separately. If required, additional amino acids may be added to the PERIKABIVEN bag or infused separately.
The recommended duration of infusion for PERIKABIVEN is between 12 and 24 hours, depending on the clinical situation.
The maximum infusion rate of PERIKABIVEN is 3.7 mL/kg/hour. This corresponds to 0.09 g/kg/hour of amino acids, 0.28 g/kg/hour of dextrose (the rate limiting factor) and 0.13 g/kg/hour of lipids.
- 1.Determine the fluid requirements (27 to 40 mL/kg/day) and the patient's nutritional requirements to be delivered, then select the corresponding PERIKABIVEN bag.
- 2.Determine the preferred duration of infusion (12 to 24 hours).
- 3.Ensure that the rate of infusion (PERIKABIVEN dosage in mL/kg/day divided by the preferred duration of infusion (hours)) does not exceed the maximum infusion rate for the patient (i.e., 3.7 mL/kg/hour). The infusion rate may need to be reduced and duration of infusion increased in order not to exceed the maximum infusion rate.
- 4.Once the infusion rate in mL/kg/hour has been selected, calculate the infusion rate (mL/hour) using the patient's weight.
- 5.Compare the patient's nutrient requirements with the amount supplied by PERIKABIVEN. Discuss with a pharmacist any additions that may be required.
Risk of Parenteral Nutrition-Associated Liver Disease
Parenteral nutrition-associated liver disease (PNALD), also referred to as intestinal failure-associated liver disease (IFALD), can present as cholestasis or hepatic steatosis, and may progress to steatohepatitis with fibrosis and cirrhosis (possibly leading to chronic hepatic failure). The etiology of PNALD is multifactorial; however, intravenously administered phytosterols (plant sterols) contained in plant-derived lipid emulsions, such as Intralipid (included in PERIKABIVEN), have been associated with development of PNALD.
In a randomized study of neonates and infants expected to be treated with PN for at least 28 days, parenteral nutrition-associated cholestasis (PNAC), a precursor to PNALD, developed more frequently in Intralipid-treated patients than in patients treated with a 4-oil mixed lipid emulsion [see Adverse Reactions (6.1), Use in Specific Populations (8.4)].
Monitor liver tests in patients treated with PERIKABIVEN and consider discontinuation or dosage reduction if abnormalities occur.
Other Hepatobiliary Disorders
Hepatobiliary disorders including cholecystitis and cholelithiasis have developed in some PN-treated patients without preexisting liver disease.
Monitor liver tests when administering PERIKABIVEN. Patients developing signs of hepatobiliary disorders should be assessed early to determine whether these conditions are related to PERIKABIVEN use.
Risk Summary
The limited available data on the use of PERIKABIVEN in pregnant women are not sufficient to inform a drug-associated risk. However, there are clinical considerations if PERIKABIVEN is used in pregnant women [see Clinical Considerations]. Animal reproduction studies have not been conducted with PERIKABIVEN.
The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-Associated Maternal and/or Embryofetal Risk
Severe malnutrition in a pregnant woman is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. Parenteral nutrition should be considered if a pregnant woman's nutritional requirements cannot be fulfilled by oral or enteral intake.
Risk Summary
There are no data available to assess the presence of PERIKABIVEN and/or its active metabolite(s) in human milk, the effects on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PERIKABIVEN, and any potential adverse effects of PERIKABIVEN on the breastfed child or from the underlying maternal condition.
Parenteral Nutrition-Associated Liver Disease and Other Hepatobiliary Disorders
Inform patients and caregivers that use of parenteral nutrition may result in parenteral nutrition- associated liver disease and/or other hepatobiliary disorders [see Warnings and Precautions (5.2)].
Pulmonary Embolism and Respiratory Distress due to Pulmonary Vascular Precipitates
Inform patients and caregivers that pulmonary vascular precipitates causing pulmonary emboli (including some fatalities) and presenting as respiratory distress have been reported in patients receiving parenteral nutrition. If PERIKABIVEN is infused at home, instruct patients or caregivers to visually inspect the prepared solution, the infusion set, and catheter for precipitates, prior to administration as well as periodically during the administration [see Warnings and Precautions (5.3)]
Hypersensitivity Reactions
Inform patients and caregivers that PERIKABIVEN may cause hypersensitivity reactions, including anaphylaxis. If PERIKABIVEN is infused at home, instruct patients or caregivers to stop the infusion of PERIKABIVEN immediately and seek medical attention if they experience signs or symptoms of a hypersensitivity reaction, such as rapid or weak heartbeat, feeling faint, difficulty in breathing or swallowing, vomiting, nausea, headache, sweating, dizziness, hives, rash, itching, flushing, dizziness, fever, or chills [see Warnings and Precautions (5.4)].
Infections
Inform patients and caregivers that patients who receive PERIKABIVEN are at risk of infection. If PERIKABIVEN is infused at home, instruct patients or caregivers to ensure aseptic techniques are used for the preparation and administration of PERIKABIVEN and to monitor for signs and symptoms of infection [see Warnings and Precautions (5.6)].
Fat Overload Syndrome
Inform patients and caregivers that fat overload syndrome has been reported with the use of intravenous lipid emulsions. If PERIKABIVEN is infused at home, instruct patients or caregivers to stop PERIKABIVEN if signs or symptoms of fat overload syndrome occur [see Warnings and Precautions (5.7)].
Refeeding Syndrome
If the patient is severely malnourished, inform patients and caregivers that administering parenteral nutrition including PERIKABIVEN may result in refeeding syndrome [see Warnings and Precautions (5.8)].
Diabetes and Hyperglycemia
Inform patients and their caregivers that administration of dextrose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, hyperosmolar coma, and death [see Warnings and Precautions (5.9)].
Hypertriglyceridemia
Inform patients and their caregivers about the risks of hypertriglyceridemia with PERIKABIVEN use [see Warnings and Precautions (5.10)].
Vein Damage and Thrombosis
Inform patients and caregivers that the infusion of hypertonic nutrient injections into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis [see Warnings and Precautions (5.11)].
Electrolyte Imbalance and Fluid Overload in Patients with Decreased Renal Function
For patients with decreased renal function, inform them or their caregivers that the patient may be at increased risk of electrolyte and fluid volume imbalance when PERIKABIVEN is being administered [see Warnings and Precautions (5.12)].
Aluminum Toxicity
Inform patients and their caregivers that prolonged PN administration in patients with renal impairment, including preterm neonates, may result in aluminum reaching toxic levels associated with central nervous system and bone toxicity [see Warnings and Precautions (5.13)].
Preparation and Administration Instructions
If it is acceptable for a patient or caregiver to administer PERIKABIVEN at home, then the patient or caregiver must be trained on the following: how to inspect and prepare, add compatible additives (when appropriate), administer, and store PERIKABIVEN [see Dosage and Administration (2.1, 2.2)]. Inform patients or caregivers not to deviate from the administration instructions given by the healthcare provider.
Manufactured by:
Fresenius Kabi Logo (Per0e 0005 25)
Uppsala, Sweden
Fresenius Kabi, Perikabiven and Intralipid are registered trademarks of Fresenius Kabi. U.S. Patents 12213943 and 12390398.
www.freseniuskabinutrition.com/products/kabiven-perikabiven/
451207G